<DOC>
	<DOC>NCT01253291</DOC>
	<brief_summary>The objective of this study is to evaluate the safety and tolerability of 48 weeks subcutaneous dosing with LY2127399 for patients who have participated in a prior LY2127399 clinical study. At the end of the 48 week treatment period, patients will participate in a 24 week follow up period. Additional follow up after week 72 may continue to assess B cell recovery.</brief_summary>
	<brief_title>A Study of Japanese Rheumatoid Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Inclusion criteria Have given written informed consent Women must not be pregnant, breastfeeding or be at risk to become pregnant during study participation Must have completed treatment and 12 week follow up period in prior LY2127399 study Exclusion criteria Have had any safety event during the study for LY2127399 that patients participated in previous Have received, during previous study, any drugs prohibited in the study protocol which includes unapproved drugs, live vaccines, or any biologic or nonbiologic DMARD except for MTX, hydroxychloroquine, sulfasalazine or bucillamine</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>